Up 90% in 2 weeks, here's why the Paradigm share price has been halted

The biopharmaceutical company is planning a capital raise.

| More on:
Female doctor with a mask holds out hand in a stop gesture.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Paradigm share price has been frozen today
  • The biopharmaceutical company has requested a trading halt pending a capital raising announcement
  • Paradigm has a number of research initiatives on the go

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is going nowhere today after the company requested a trading halt. 

The Paradigm share price has rocketed from $1.05 per share on 28 July to $1.99 per share at Wednesday's close, a gain of 89.5%. 

Across this timeframe, the ASX-listed biopharmaceutical company released its quarterly results for the three months ended 30 June 2022 and announced the results of a major research project.

Before market open this morning, it entered a trading halt pending an announcement relating to a capital raising.

Let's dive deeper to get up to speed with what's happening at Paradigm. 

Why is Paradigm in a trading halt?

The Paradigm share price has been frozen today after the company requested a trading halt in relation to a capital raising.

It will remain halted until the start of normal trading on Monday or when the announcement is released to the market, whichever comes first.

The company burned $32 million of cash for FY22 and the cash balance at 31 December 2021 was nearly $55 million. It seems Paradigm wants to solidify its capital base to progress the research initiatives outlined below. 

In its last announcement on Monday, Paradigm reported it will be presenting the results of its drug development to treat the metabolic disease mucopolysaccharidoses (MPS) type I in February next year. 

Paradigm's long-term goal is to develop an injectable form of pentosan polysulfate sodium (PPS) to treat MPS. Historically, PPS has primarily been used to assist with bladder pain.

In addition, Paradigm is researching the use of PPS for a range of other clinical uses, such as treating pain in patients suffering from musculoskeletal disorders. 

Paradigm share price snapshot

The Paradigm share price is up 45% in the last six months and 87% over the past month. It has also gained 4% this year to date.

In contrast, the S&P/ASX 200 Index (ASX: XJO) has declined by 2% across the last six months and 7% year to date, but is up almost 7% in the past month.

The recent rapid rally in the Paradigm share price has been spurred by some positive developments. However, investors should be aware that Paradigm's net loss has been on a downward trend from FY17 to FY21.

The recent momentum has driven Paradigm's market capitalisation to around $450 million.

Motley Fool contributor Raymond Jang has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Capital Raising

Man with his hand out, symbolising a trading halt.
Technology Shares

Why is the Appen share price frozen today?

This high-flying AI stock has requested a trading halt this morning.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Capital Raising

Guess which ASX 300 copper stock is crashing 12% today

Let's see what is causing this stock to sink deep into the red.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Capital Raising

Why is this ASX 300 stock crashing 18% today?

Let's see what is making investors hit the sell button today.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Why is this ASX All Ords stock sinking 14% on Friday?

Let's see why investors hitting the sell button today.

Read more »

Data Centre Technology
Capital Raising

NextDC share price drops on $750m capital injection for Asian expansion

The data centre operator is raising funds to support its expansion.

Read more »

Kid stacking coins from the jar.
Capital Raising

This ASX 300 stock is rising after completing its next step for Canadian growth

Expanding in Canada could be a patently good idea.

Read more »

Successful group of people applauding in a business meeting and looking very happy.
Capital Raising

Guess which ASX All Ords stock is leaping 9% after raising $60 million

This fast-growing company is maintaining a lean balance sheet while making an accretive acquisition.

Read more »

A robot grimaces and looks alarmed as it sits frozen in ice.
Capital Raising

Up 140% in a month, here's why this high-flying ASX small-cap stock has just been frozen

This ASX robotics company requested a trading halt today.

Read more »